A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
Clinical trial NCT06182592 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06182592
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-01
- Primary completion
- 2026-02-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.